Treatment considerations for Behcet disease in the era of COVID-19: A narrative review

Basit Öğe Kaydı
dc.contributor.authorElmas, Omer Faruk
dc.contributor.authorDemirbas, Abdullah
dc.contributor.authorBagcier, Fatih
dc.contributor.authorTursen, Umit
dc.contributor.authorAtasoy, Mustafa
dc.contributor.authorDursun, Recep
dc.contributor.authorLotti, Torello
dc.date.accessioned2024-02-23T14:24:07Z
dc.date.available2024-02-23T14:24:07Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractCOVID-19 is a multisystem disease caused by severe acute respiratory syndrome coronavirus 2. It has been declared a pandemic by the World Health Organization in March 2020 and the outbreak still keeps its impacts worldwide. Behcet disease (BD) is a multi-systemic vasculitis involving the skin, mucosa, eyes, joints, nervous system, cardiovascular system, and gastrointestinal system. The precise etiopathogenesis of the disorder is unknown but autoimmunity is believed to play a key role. A considerable part of patients with BD are susceptible to immunosuppression and are more predisposed to infections than healthy individuals. Hence, the protection and control measures for patients with BD against the COVID-19 are of the utmost significance. Given the requirement to balance proper treatment of BD with the smallest risk of COVID-19 associated mortality and morbidity, we aimed to review the management of BD in the era of the pandemic with a special focus on treatment considerations. According to current expert recommendations, there is no reason to discontinue topical treatments, colchicine, and nonsteroidal antiinflammatory drugs. Systemic steroids can be used at the lowest possible dose if needed. Ongoing treatments can be continued unchanged in patients with no suspected or confirmed COVID-19. In cases with COVID-19 symptoms, immunosuppressive and biological agents can be temporarily stopped but the decision should be made on a case by case basis. Considering their potential beneficial effects on the course of COVID-19, colchicine, pentoxifylline, and dapsone can be considered as safe treatment options in BD.en_US
dc.identifier.doi10.1111/dth.14507
dc.identifier.issn1396-0296
dc.identifier.issn1529-8019
dc.identifier.issue1en_US
dc.identifier.pmid33150651en_US
dc.identifier.scopus2-s2.0-85096675858en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1111/dth.14507
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13828
dc.identifier.volume34en_US
dc.identifier.wosWOS:000587635600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofDermatologic Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBeh-Et Syndromeen_US
dc.subjectColchicineen_US
dc.subjectCovid-19en_US
dc.subjectSars-Cov-2en_US
dc.titleTreatment considerations for Behcet disease in the era of COVID-19: A narrative reviewen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu